問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of General Surgery

Division of General Internal Medicine

Digestive System Department

更新時間：2023-09-19

楊再勝Yang, Tsai-Sheng
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

Recruiting Trial

67Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊再勝

List

166Cases

2015-12-01 - 2026-12-31

Phase II

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
8Sites

Recruiting8Sites

2019-03-01 - 2023-12-31

Phase III

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    Cabozantinib (XL184) 20mg and 60mg tablet; Atezolizumab 1200mg/ 20ml solution for IV infusion

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites

2015-09-01 - 2018-12-31

Phase II

A Phase 1b/2 Study of MEDI4736 in Combination with Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects with Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

  • Condition/Disease

    Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    Durvalumab (MEDI4736), Tremelimumab

Participate Sites
3Sites

Terminated3Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2010-07-01 - 2011-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2009-07-01 - 2011-06-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2007-09-01 - 2009-09-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2021-01-02 - 2023-06-02

Phase I

A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    AMG 404

Participate Sites
2Sites

Recruiting2Sites

2020-11-01 - 2022-03-11

Phase II

A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor–Naïve With Selected Solid Tumors

  • Condition/Disease

    Non Small Cell Lung Cancer / Urothelial Cancer / Renal Cell Carcinoma / Hepatocellular Carcinoma / Melanoma

  • Test Drug

    INCB086550

Participate Sites
7Sites

Recruiting3Sites

Terminated4Sites

2019-11-01 - 2023-01-31

Phase II/III

A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cance

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Bintrafusp alfa (M7824)

Participate Sites
7Sites

Recruiting7Sites

2019-11-01 - 2025-02-28

Phase III

A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib (Rivoceranib) Mesylate Versus Sorafenib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy

  • Condition/Disease

    Advanced Hepatocellular Carcinoma (HCC)

  • Test Drug

    Camrelizumab (SHR-1210)、Rivoceranib (Apatinib) mesylate

Participate Sites
8Sites

Recruiting8Sites

1 10 11 12 13 14 17
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB